NASDAQ: COLLCollegium Pharmaceutical Inc Stock
$34.77-0.68 (-1.92%)
Updated Apr 18, 2024
COLL Price
$34.77
Fair Value Price
$48.26
Market Cap
$1.11B
52 Week Low
$20.83
52 Week High
$40.95
P/E
24.31x
P/B
5.69x
P/S
1.83x
PEG
0.35x
Dividend Yield
N/A
Revenue
$566.77M
Earnings
$48.16M
Gross Margin
57.5%
Operating Margin
28.07%
Profit Margin
8.5%
Debt to Equity
4.85
Operating Cash Flow
$275M
Beta
0.93
Next Earnings
May 2, 2024
Ex-Dividend
N/A
Next Dividend
N/A
COLL Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how COLL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COLL ($34.77) is undervalued by 27.96% relative to our estimate of its Fair Value price of $48.26 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
COLL ($34.77) is significantly undervalued by 27.96% relative to our estimate of its Fair Value price of $48.26 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
COLL ($34.77) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COLL due diligence checks available for Premium users.
Be the first to know about important COLL news, forecast changes, insider trades & much more!
COLL News
Valuation
COLL fair value
Fair Value of COLL stock based on Discounted Cash Flow (DCF)
Price
$34.77
Fair Value
$48.26
Undervalued by
27.96%
COLL ($34.77) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COLL ($34.77) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COLL ($34.77) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COLL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
24.31x
Industry
46.58x
Market
41.33x
COLL is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
COLL is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
COLL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.69x
Industry
2.04x
COLL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COLL price to earnings growth (PEG)
For valuing profitable companies with growth potential
COLL is good value based... subscribe to Premium to read more.
PEG Value Valuation
COLL's financial health
Profit margin
Revenue
$149.7M
Net Income
$31.9M
Profit Margin
21.3%
COLL's Earnings (EBIT) of $159.07M... subscribe to Premium to read more.
Interest Coverage Financials
COLL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.1B
Liabilities
$947.9M
Debt to equity
4.85
COLL's short-term assets ($537.60M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COLL's short-term assets ($537.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COLL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
COLL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$73.3M
Investing
-$25.1M
Financing
-$67.8M
COLL's operating cash flow ($274.75M)... subscribe to Premium to read more.
Debt Coverage Financials
COLL vs Pharmaceutical Stocks
Collegium Pharmaceutical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.